361 Capital’s LeMaitre Vascular LMAT Stock Holding History

361 Capital’s Portfolio LMAT Stock Details LMAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-52,722	Closed	-$1.97M	–	274
2017 Q3	$1.97M	Buy	+52,722	New	+$1.79M	0.38%	146

Other funds holding LMAT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EIP

Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RIM

Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return

TAM

THB Asset Management Norwalk, Connecticut $440M AUM 59.59% 1-Year Est. Return

361 Capital's LMAT Position: Q4 2017 in Review

361 Capital sold out of LeMaitre Vascular (LMAT) in Q4 2017, closing a stake of 52,722 shares — an estimated $1.97M sold.

361 Capital first reported a position in LMAT in Q3 2017 and held it in 1 quarter. The position peaked at $1.97M in Q3 2017. 142 funds tracked by Wall St. Rank hold LMAT as of Q4 2017.

361 Capital reported no remaining LeMaitre Vascular position as of Q4 2017 after selling out during the quarter.
361 Capital sold 52,722 LeMaitre Vascular shares in Q4 2017, an estimated $1.97M.
361 Capital first reported a position in LeMaitre Vascular in Q3 2017 and held it in 1 quarter.
361 Capital's LeMaitre Vascular position peaked at $1.97M in Q3 2017.
142 funds tracked by Wall St. Rank held LeMaitre Vascular as of Q4 2017.

Based on 361 Capital's 13F filing for Q4 2017, filed 14 Feb 2018.